Imetelstat Sodium (GRN163L)

DRUG4 trials

Sponsors

Geron Corporation

Conditions

Lung CancerMultiple MyelomaSolid Tumor Malignancies

Phase 1

Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

CompletedNCT00310895

Geron CorporationSolid Tumor Malignancies

Start: 2006-03-31End: 2013-03-31Target: 85Updated: 2015-12-24

Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

CompletedNCT00510445

Geron CorporationLung Cancer

Start: 2007-07-31End: 2011-04-30Updated: 2015-12-24

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

CompletedNCT00594126

Geron CorporationMultiple Myeloma

Start: 2007-11-30End: 2011-07-31Updated: 2015-12-24

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

CompletedNCT00718601

Geron CorporationMultiple Myeloma

Start: 2008-07-31End: 2011-10-31Target: 40Updated: 2015-12-24